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ORIGINAL RESEARCH
The prognostic role of NK cells and their ligands in squamous cell carcinoma of the
head and neck: a systematic review and meta-analysis
Sangeeta K. Bisheshar a, Emma J. De Ruitera, Lot A. Devrieseb, and Stefan M. Willemsa
aDepartment of Pathology, University Medical Center Utrecht, CX Utrecht 3584, The Netherlands; bDepartment of Medical Oncology, University
Medical Center Utrecht, CX Utrecht 3584, The Netherlands
ABSTRACT
Background: Despite the improvement in therapeutic interventions, 5-year survival rates in Head and
Neck Squamous Cell Carcinoma (HNSCC) are limited. HNSCC is an immunogenic cancer type for which
molecular stratification markers are lacking. Tumor-infiltrating lymphocytes (TILs) have shown
a favorable prognostic role in different cancer types. This study focused on the prognostic role of NK
cells in HNSCC.
Methods: A systematic search was conducted in Pubmed/Medline and Embase. Articles that correlated
the presence of intratumoral NK cells, activating/inhibiting receptors, death receptors, or their ligands
with clinicopathologic characteristics or survival were included. A meta-analysis was performed that
assessed the association between CD56+ and CD57+ and overall survival (OS), disease-free survival
(DFS), and progression-free survival (PFS).
Results: A pooled analysis indicated a favorable prognostic role of CD56+ and CD57+ NK cells for OS (HR
0.19 CI 0.11–0.35). NK cell markers NKp46 and Granzyme B (GrB) also have a favorable prognostic role.
NK cell ligand Fas correlated with better survival and better characteristics. NK cell marker Fas-L, NK cell
ligands CEACAM1, RCAS1, CD70 and TRAIL-R, and effector molecules of these ligands, FADD and FAP1,
correlated to features of worse prognosis.
Conclusion: A favorable prognostic role of NK cells in HNSCC was found in this review. Some studies
implied the opposite, indicating the fine balance between pro- and anti-tumor functions of NK cells.
Future studies using homogeneous patient cohorts regarding tumor subsite and treatment modality, are
necessary to further provide insight into the prognostic role of NK cells.
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The majority of Head and Neck Cancers (HNC) comprise
squamous cell carcinomas arising from the stratified epithe-
lium of the oral cavity (OC), nasopharynx (NP), hypopharynx
(HP), oropharynx (OP) and larynx (L).1 HNC is the sixth
most common cancer worldwide with approximately 600,000
new cases per year.2,3 The mortality due to Head and Neck
Squamous Cell Carcinoma (HNSCC) is 380.000 per year,
making it the seventh most common cause of cancer-related
mortality worldwide.4 In recent decades, research has focused
on identifying prognostic biomarkers in HNSCC to counter-
act major issues: late diagnosis and locoregional recurrence.
The archetypal patient with HNSCC is of male gender
between the ages of 50–70 years, with a history of tobacco
and alcohol use, both identified as risk factors.5 Over the last
decades another risk factor has been identified: the human
papillomavirus (HPV). The most HPV positive HNSCC
occurs in the oropharynx of a younger population.6,7
Roughly 60% of HNSCC patients have an advanced stage
disease at the time of diagnosis, due to limited awareness and
knowledge of alarm symptoms, and the characteristic rapid
proliferation of HNSCC.8 Currently, treatment methods are
insufficient; locoregional recurrence occurs in 15-50% of
patients,9 and for all clinical stages combined, five-year survi-
val rates are between 56%-62%.10,11 This calls for reliable
prognostic biomarkers that enable clinicians to stratify
patients in risk groups and treating them accordingly,
improving personalized medicine. Cancer development is
facilitated by the inability of the immune system to recognize
and eliminate tumor cells. In HNSCC, an immunogenic can-
cer type, immune escape mechanisms are key to tumor initia-
tion and progression. Since the host immune system plays an
important role in the development of cancer, the scientific
necessity arose to further employ the immune system for the
treatment of HNSCC. Currently, cetuximab, an EGFR
(endothelial growth factor receptor) inhibitor, is used in case
a contradiction for chemotherapy exists.12,13 The antitumor
effect of cetuximab is strengthened by binding the FcY recep-
tor on NK cells enabling antibody-dependent cellular cyto-
toxicity (ADCC).14
Immunological markers have shown to be prognostic indi-
cators, even superior to the TNM staging system.15 In lung,
colorectal and breast cancer, studies have shown that tumor-
infiltrating lymphocytes have a favorable prognostic role.16–18
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A meta-analysis conducted by de Ruiter et al. (2017) reports
findings in concordance with the latter for HNSCC.19
NK cells are an essential component of the innate immune
system as an early line of defense against tumor cells and act
by killing them. They could, therefore, function as
a prognostic biomarker in HNSCC. NK cell subpopulations
can be defined based on CD56 expression on the surface of
the cells, in which CD56bright cells express a relatively high
density of CD56 and CD56dim cells express the relatively low
density of CD56. Classically, NK cells are divided in
CD56bright CD57− immune regulatory cells and CD56dim
CD57+ cytotoxic cells.20 In most studies CD56 is the arche-
typal phenotypic marker of NK cells.21 Another marker,
CD57, is a marker of differentiated and highly cytotoxic NK
cells and is often used in studies, as it has been described as
a phenotypically stable NK cell marker.22
NK cells are regulated by activating membrane-bound
receptors that enable lysis of target cells that fail to express
sufficient levels of MHC class 1 (missing self hypothesis) and
by inhibitory receptors that protect cells that do express MHC
class 1. These inhibitory and activating receptors are killer-cell
immunoglobulin like receptors (KIRs). Important activating
receptors are NKG2D, that has MICA/B as a ligand, and
NpK30, NpK44, and NpK46, that have a broad variety of
ligands. Upon activation, NK cells release granules containing
perforin and granzymes, and produce cytokines, causing cell
death. NK cells also express death receptor ligands (Fas-L,
TNF-α, TRAIL), that induce cell death upon binding death
receptors (Fas, TRAIL-R (DR4, DR5)) on target cells.23 These
receptors can serve as potential markers for NK cells in
HNSCC. In breast and colorectal cancer, reviews report that
NK cells are of positive prognostic value.24,25
Objectives
This study was conducted to shed light on the prognostic role
of NK cells and their ligands in HNSCC by systematically
reviewing the literature. The main goal was to include all
studies that assessed tumor infiltration with CD56+ and/or
CD57+ lymphocytes, NK cell-activating/inhibiting receptors,




The initial search yielded 3520 references, after the removal of
180 duplicates. After title/abstract screening, reviewers SKB
and ERU selected 122 articles, which were subjected to full-
text reading. Of the selected 122 articles, 9 were not available,
4 were in Chinese, 1 in German, 1 had missing data and 61
did not comply with our inclusion criteria regarding the
determinant, domain and/or methods. Of the 46 articles that
were eligible for inclusion, 13 assessed classical NK cell
markers.26–38 The activating markers group existed of three
articles,39–41 the inhibiting markers group of 542–46 and the
death receptor group of 25.47–71 Figure 1 provides an overview
of study selection.
Critical appraisal
Critical appraisal for risk of bias was applied on the 13 articles
of the classical markers group by use of the QUIPS criteria.
All studies scored poorly in the study attrition domain,
because none of the studies mentioned the patient’s loss to
follow-up. This domain was therefore not considered when
assessing the overall risk of bias. Because assessing survival
analysis by hazard ratios is crucial for conducting a meta-
analysis, studies that did not mention hazard ratios were
excluded. Exclusion was therefore not based on total bias
score. The quality assessment is shown in Table 1. The four
articles that mentioned hazard ratios26–29 were selected for
meta-analysis after critical appraisal; the forest plot is shown
in figure 2.
Classical markers as a predictor for survival
A total of six studies reported on CD56+ cells. The presence
of CD56+ NK cells was associated with a better OS (Wagner
et al.: HR 0.32, CI 0.10–0.96, p 0.04; Stangl et al.: HR 0.27, CI
0.12–0.60, p 0.001), local PFS (Stangl et al.: HR 0.35, CI
0.17–0.74, p 0.005) and distant metastasis-free survival
(DMFS) (Stangl et al.: HR 0.27, CI 0.13–0.55, p 0.004).
A total of seven studies reported on CD57+ cells. High num-
bers of CD57+ NK cells were associated with a better OS
(Fang et al.: HR 0.15 CI 0.06–0.36 p < .001; Taghavi et al.:
HR 0.06 CI 0.01–0.26 p < .001).26–30 The pooled meta-analysis
showed an advantage for high CD56+/CD57+ NK cells
regarding OS (pooled HR 0.19 CI 0.11–0.35) (Figure 2).
Some studies mentioned no correlation between CD56+ NK
cell number and OS or recurrence-free survival (RFS) or
between CD57+ NK cells and OS (de Carvalho Fraga et al.:
OR 1.04,CI 0.44–2.46, p 0.93) or DFS.31–35 One study reported
on CD16+ cells and found no correlation between CD16
+ cells and DFS.36
Classical markers as a predictor for clinicopathologic
characteristics
Next, the correlation between classical markers and the
known clinicopathologic characteristics that influence prog-
nosis was investigated. One study found that high infiltration
of CD57+ cells correlated with T3/T4 tumors and cervical
metastasis (de Carvalho Fraga et al.: resp. OR 5.610, CI 1.-
516–20.763, p 0.010 and OR 3.401, CI 1.162–9.951, p 0.025).
These results indicate that in this study CD57+ cells corre-
lated with features of worse prognosis.40 Contradictory, many
studies mention the correlation of high CD57+ cell number
with features of better prognosis; absence of lymph node
metastasis, early clinical stages.37,38 Other studies have noted
a trend toward features of better prognosis; fewer cases of
nodal metastasis, advanced-stage disease, disease relapses,
lower probability of local recurrence (LR) and death.39,45
One study mentioned a higher number of CD56+ NK cells
in a study group without metastatic disease.46 Another study
found no correlation between CD16+ NK cells and tumor
location, TNM stage, or recurrence of the disease.44
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Supplementary Table 2 mentions the characteristics of the
studies that assessed classical markers.
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Figure 1. Flow chart of the 3520 articles initially selected, 49 were included after full-text screening. (Moher et al. 2009. prisma flow chart).98.
















Lazaris 2009 2 2 1 0 0 2 5
Zancope 2010 0 2 1 0 2 1 4
Fraga 2011 0 2 0 2 0 0 2
Sakakura 2014 0 2 0 0 2 2 4
Wagner 2015 0 2 0 0 0 0 0
Stangl 2016 0 2 0 0 0 0 0
Taghavi 2016 1 2 0 0 2 0 3
Fang 2017 1 2 0 0 1 0 2
Kartpathiou 2017 0 2 0 0 0 2 2
Maciel 2017 1 2 0 0 2 0 3
Stasikowska 2017 2 2 2 2 1 0 7
Schoenfeld 2018 0 2 0 0 2 0 2
Santos 2019 0 2 0 2 0 0 2
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Activating markers as predictors for survival and
clinicopathologic characteristics
A total of two studies reported on NKp46+ NK cells; one
study mentioned that NKp46+ NK cells alone were not asso-
ciated with survival and the other study reported that NKp46
+ NK cells were more abundant in low-grade tumors.39,40
One study investigated the prognostic role of tumoral
CD70 expression. Tumoral CD70 expression was higher in
poorly differentiated carcinomas. There was no correlation
with TNM stage. High tumor CD70 expression correlated
with a trend toward lower density of TIL’s.41
Inhibiting markers as predictors for survival and
clinicopathologic characteristics
A total of four studies reported on CEACAM1. Three studies
mentioned that high CEACAM1 expression correlated with
worse survival and features of worse prognosis; high tumor
grade, local recurrence, lymph nodemetastasis, distantmetastasis,
and high clinical stage.42–45 One study mentioned contradictory
results and found that high CEACAM1 expression correlates with
better OS and DFS and features of better prognosis.43
RCAS1 expression in tumor cells was investigated in one
study, which found that it was associated with high-grade
tumors and the presence of lymph node metastasis.46
See Table 2 for a summary of outcomes and supplementary
Table 3 for study characteristics of the activating and inhibit-
ing markers.
Death receptors as predictors for survival and
clinicopathologic characteristics
A total of four studies reported on Fas or Fas-L and four other
studies reported on both markers.
Fas expression in tumor cells correlated with negative lymph
nodes (de Carvalho-Neto et al.: OR 5.02 CI 1.34–18.75 p 0.017),
absence of LR, lower clinical stage, better OS, better disease-
specific survival (DSS) (de Carvalho-Neto et al.: HR 0.268 CI
0.083–0.862 p 0.027).49,50,53 Contradictory, one studymentioned
Fas expression associated with a higher clinical stage.47
Fas-L expression in the tumor is correlated with higher
T stage, N stage, clinical stage, and worse DFS (de Carvalho-
Neto et al.: HR 2.58 CI 1.03–6.46 p 0.044).47,50,52,57 One study
mentioned that strong Fas-L expression in lymphoid cells was
associated with lymph node metastasis, low DFS, and low DSS
(Peterle et al.: resp. OR 5.39 CI 1.30–22.34 p 0.02, HR 2.24, CI
1.08–4.65 p 0.03 and HR 2.49 CI 1.04–5.99 p 0.041).51 Some
studies mention no correlation of Fas or Fas-L expression
with OS, DFS, DSS, or clinicopathologic parameters.48,54-56,58
A total of eight studies investigated the prognostic role of
FADD. High FADD expression correlated with the presence of
lymph node metastasis, higher tumor grade, worse DSS, worse
DFS (Chien et al.: HR 1.684 CI 1.209–2345 p 0.002; Fan et al.: HR
1.003 p 0.0006), shorter DMFS (Pattje et al.: HR 2.3 CI 0.96–5.7
p 0.062) and worse OS (Chien et al.: HR 1.387 CI 1.035–1.859
p 0.029; Fan et al.: HR 1.004 p 0.000; Rasamny et al.: OR 1.72 CI
1.14–2.60 p 0.01).59–63,66 One study found that high FADD
expression showed a trend toward better local-regional control
(LRC) (Schrijvers et al.: HR 3.66 CI 0.85–15.66 p 0.081), but
reported no correlation with clinicopathologic parameters or
OS.64 Another study found no correlation between FADD
expression and clinicopathologic characteristics or survival.65
Three studies reported on the prognostic role of TRAIL. The
first one mentioned that high TRAIL expression correlated to
worse OS.67 The second study mentioned a positive correlation
between tumor stage and TRAIL-R DR5 staining, although this
correlation is on the edge of significance. TRAIL and other
TRAIL-R were not associated with clinicopathologic
Figure 2. Forest plot of prognostic value of CD56+/CD57+ NK cells on overall survival; high CD56/CD57 cell count correlated with better overall survival (HR 0.19, CI
0.11–0.35). (RevMan 2014).99.
Table 2. The outcomes of activating and inhibiting marker studies are summarized based on high expression of the markers in question. Oral Cavity (OC),
Oropharynx (OP), Hypopharynx (HP), Larynx (L), Lip (Lip), Tongue (T). Overall survival (OS), Disease-free survival (DFS), Progression-free survival (PFS), Distant
metastasis-free survival (DMFS), Disease-specific survival (DSS), Local recurrence (LR), Local-regional control (LRC).
Marker
(High expression) Study Sample Size Subsite Outcome
NKP46 Ikeda 2017 41 OC No correlation with survival or characteristics
Ladanyi 2018 50 OP, HP, L, OC Low grade tumors
CD70 De Meulenaere 2016 95 OP, HP, L, OC Poorly differentiated carcinomas, Lower density TIL’s
CEACAM1 Shinozuka 2009 78 OC High expression in T1 and T2 groups, Early stage disease, Better OS and DFS
Wang 2013 74 T High clinical stage, Lymph node metastasis
Lucarini 2018 54 L High tumor grade, LR, Lymph node- and distant metastasis
Simonetti 2018 40 OC Worse OS, Worse DSS, High tumor grade
RCAS1 Dutsch Wicherek 2009 102 OP, HP, L High tumor grade, Lymph node metastasis
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characteristics and survival.68 The third study mentioned that in
their specimens, TRAIL staining was scarce. However, they inves-
tigated TRAIL-R and found that TRAIL-R DR5 positively corre-
lated with tumor size.69
One study investigated the prognostic role of Granzyme
B (GrB) and found that there was a higher peritumoral den-
sity of Granzyme B in the non-metastatic study group in
comparison with the metastatic study group. High peritu-
moral GrB correlated with better survival. GrB was higher in
tumors with lower T stages, although not statistically
significant.70
Another study investigated the prognostic role of FAP-1
and found that FAP-1 negative cases showed a better OS than
FAP-1 positive cases (Nariai et al.: HR 0.317 CI 0.108–0.931
p 0.0366).71
See Table 3 for outcomes and supplementary table 4 for
study characteristics.
Discussion
To date, specific-validated prognostic biomarkers are an
unmet need to improve HNSCC treatment. NK cells are of
innate origin, but also carry out the functions of the adaptive
immune system. The immune system is a key component in
tumor growth and control, and as such NK cells act as good
candidates for possible biomarkers, due to their ability to lyse
tumor cells lacking sufficient levels of MHC class 1. In this
review, we investigated the prognostic role of NK cell markers
and their ligands in HNSCC. The studies included in this
review largely stem from the pre-immunotherapy era and
should be interpreted accordingly.
Firstly, the prognostic role of the classical NK cell markers
CD56+, CD57+, and CD16+ was investigated. Our meta-
analysis describes that high CD56+ or CD57+ NK cell count
correlated to better OS. This result can be explained by the
anti-tumor response of NK cells, as they are able to kill tumor
cells without prior sensitization.72 CD56dim CD57+ NK cell
subtypes are important in anti-tumor immunity and also
express CD16.13,73 CD16 is the activating FcY receptor for
IgG, that enables antibody-dependent cell-mediated cytotoxi-
city (ADCC) when crosslinked to CD57.74 One study investi-
gated the prognostic role of CD16+ NK cells, and found no
correlation with survival or clinicopathologic characteristics.
Important activating receptors are NKG2D, that has
MICA/B as a ligand, and NKp30, NKp44, NKp46, that have
a broad variety of ligands.23 Tumor cells express NK activat-
ing receptor ligands de novo, making them susceptible to NK
cell killing.75 In this review we found that NKp46+ NK cells
were more abundant in low-grade tumors, indicating
a positive role of NK cells in tumor control.
One study, however, found contradictory results; high
CD57+ NK cell number correlated to features of worse prog-
nosis. This could be explained by the phenomenon of tumor
escape mechanisms; escaping immune recognition by selective
loss of NK activating receptor ligands, aberrant HLA types or
induction of anergy in NK cells.72,76 Absence of MHC pro-
tects against T cell activation, but enables NK cell-mediated
killing of tumor cells. In this regard, a great portion of
HNSCC have resorted to expressing abnormal MHC types,
that shield against both T cell and NK cell activation.77 Korrer
et al. (2017) mention the upregulation of NK cell inhibitory
ligand NKG2A on tumor-associated NK cells in HNSCC as an
immune escape mechanism.78
Table 3. The outcomes of death receptor studies are summarized based on high expression of the markers in question. Oral Cavity (OC), Oropharynx (OP),
Hypopharynx (HP), Larynx (L), Lip (Lip), Tongue (T). Overall survival (OS), Disease-free survival (DFS), Progression-free survival (PFS), Distant metastasis-free survival
(DMFS), Disease-specific survival (DSS), Local recurrence (LR), Local-regional control (LRC).
Marker (High
expression) Study Sample Size Subsite Outcome
Fas and Fas-L Fuijeda 2000 58 OC, OP No correlation with T stage, N stage, clinical stage, LR, OS, DFS
Guler 2005 26 OC, OP High clinical stage
Tsuzuki 2005 58 OP No correlation with OS
De Carvalho-Neto
2013
60 OC Fas: Negative lymph nodes, better DSS
Fas- L: Worse DFS
Fas Bayazit 2000 30 L No correlation with T stage, N stage, Tumor grade, Tumor site
Muraki 2000 46 OC Better OS, Absence of LR, lower clinical stage.
Jackel 2001 88 L No correlation with OS, DSS or clinicopathologic parameters
Asensio 2007 45 L Better survival
Fas-L Reichert 2002 28 OC No correlation with T -or N stage
Das 2011 41 OC High clinical stage, higher T and N stage (not statistically significant)
Fang 2013 38 OC Lymph node metastasis
Peterle 2015 64 OC Fas-L expression in lymphoid cells correlated with lymph node metastasis, low
DFS and low DSS
FADD Prapinjumrune
2009
60 T Cervical lymph node metastasis, Worse DSS
Schrijvers 2011 92 L Trend toward better LRC, No correlation with OS or clinicopathologic
parameters
Rasamny 2012 222 OP, OC, HP, NP Worse OS, DSS and DFS
Pattje 2012 177 OP, HP, L, OC Lymph node metastasis, Shorter DMFS
Fan 2013 200 OP, OC, L Worse OS and DFS
Chien 2016 339 OP, HP, OC Lymph node metastasis, Younger age, Higher tumor grade, Worse DFS and OS
Wachters 2017 60 L No correlation with survival or clinicopathologic parameters
Noorlag 2017 158 OC Lymph node metastasis
TRAIL Vigneswaran 2007 45 OC High TRAIL-R DR5: higher T stage
Carcini 2010 134 OC Worse OS
Erkul 2016 20 L High TRAIL-R DR5: higher clinical stage
GrB Costa 2010 55 OC Better survival, Lower T stages
FAP-1 Nariai 2011 50 OC Worse OS
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The CD27-CD70 pathway enhances the cytotoxic effect of
effector cells via the perforin dependent mechanism.79 CD70
expression in the tumor should, therefore, promote NK cell
killing. In this review CD70 expression correlated with fea-
tures of worse prognosis, indicating the opposite. This could
be explained by another hypothesis; that CD27-CD70 path-
way is a mechanism of immune escape for tumor cells by
inducing apoptosis in effector cells.80
The inhibiting ligands CEACAM1 and RCAS1 correlated
with features of worse survival and prognosis. CEACAM1 is
expressed on tumor cells and NK cells, and an interaction
inhibits tumor cell lysis by NK cells, as it is an inhibiting
receptor/ligand.81 It also inhibits the activating NKG2D signal-
ing, thus a high expression of CEACAM1 inhibits NK cell
antitumor function. RCAS1 plays a role in immune evasion of
tumor cells by inducing apoptosis in NK cells, thus correlating
with features of worse prognosis in HNSCC. This is in concor-
dance with other studies, that mention a correlation with fea-
tures of worse prognosis in pancreatic ductal cell carcinoma and
shorter survival in esophageal squamous cell carcinoma.82,83
Lastly, NK cells also express death receptor ligands (Fas-L,
TNFa, TRAIL), which mediate apoptosis by binding to death
receptors (Fas, TRAIL-R (DR4, DR5)) on target cells.16 These
death receptors are also expressed on T cells; the results
mentioned in the following paragraph need to be interpreted
as a synergistic result of T cells and NK cell function.
Regarding the direct relationship between NK cells and
death receptors/ligands, expression of the latter on T cells is
a confounding factor.84
NK and T cell ligand Fas expressed on tumor cells, corre-
lated to better survival and better clinicopathologic character-
istics in HNSCC and this is in concordance with some other
cancer types.85,86 However, one study found a correlation with
features of worse prognosis. Tumor cells use escape mechan-
isms to become resistant to Fas mediated apoptosis, for
instance by downregulation of FADD, causing loss of apop-
totic signaling.87 The classic function of FADD is inducing
apoptosis in cells via stimulation of different death receptors.
But the FADD oriented studies included in this review found
that high expression of FADD correlated to a worse prog-
nosis. Latter finding was previously reported by researchers in
data from The Cancer Genome Atlas (TCGA).88
It indicates a more complex and unresolved role of FADD,
as it can also, for example, activate the NFkB pathway and
induce cell survival.63 Fas-L on NK and T cells mediates
apoptosis when coupled to Fas on tumor cells, but one article
mentioned Fas-L on NK and T cells correlated to worse
survival and features of worse prognosis. Fas-L expression in
tumor cells also correlated to worse survival, the hypothetical
explanation for this effect is ‘tumor counterattack.’89 By
expressing Fas-L, the tumor induces apoptosis in lymphoid
cells. TRAIL-R expression in the tumor correlated to worse
prognosis, this might be explained by the use of decoy recep-
tors to evade apoptosis induction.69 FAP-1 is a regulating
molecule blocking Fas-mediated apoptosis, thus explaining
the result that low FAP 1 correlated to a better prognosis.90
For some markers/ligands (GrB, NKp46, RCAS1, FAP1)
the findings confirm the proposed pathophysiological
mechanism as described in the literature. The other makers/
ligands (CD56, CD57, CD70, CEACAM1, Fas, Fas-L, FADD,
TRAIL) show bivalent results indicating more complex
mechanisms underlying their function and prognostic role.
The findings of this review are bivalent, indicating a fine
line between the anti- and pro-tumor function of NK cells.
Previous studies identified this as an opportunity to use NK
cells as a therapeutic strategy, tackling the unmet need for
immunotherapy development. NK cells are good candidates;
they recognize tumor cells by lack of sufficient MHC type 1
levels, subsequently activating NK cell stimulatory receptors,
mediating NK cell killing. This distinctive method of NK cell
killing avoids the conundrum T cell-based therapies face;
dependability on presentation of specific antigens (e.g. tumor-
specific antigens, tumor-associated antigens or differentiation
antigens) on MHC in order to activate T cell killing. In
HNSCC and various other tumor types, loss of tumoral
MHC expression has been described, impairing T cell-
mediated cytotoxicity.91-93
NK cells are known for their robust anti-tumor immunity,
which is often impaired in cancers. NK cell immunotherapy,
therefore, focuses on restoring the antitumor response, for
example, by retargeting strategies with therapeutic antibodies
or chimeric antigen receptors (CARs), by blocking KIRs with
therapeutic antibodies (Lirilumab), by NK cell checkpoint
inhibitors (Monalizumab: NKG2A inhibitor) or by NK cell-
based adoptive immunotherapy.87,94,95 Furthermore, TRAIL-
R agonists propose as promising modulators in antitumor
immunity.96 Future research is needed to provide insight in
the clinical translation of the NK cell immunotherapies.
The first general limitation of this study is heterogeneity
in tumor subsite, among and within studies included in this
review. In HNSCC, risk factors and pathophysiological
mechanisms differ between different tumor subsites in the
head and neck region, which could impact the prognostic
role of NK cells among these subsites. Secondly, the studies
showed heterogeneity in treatment modalities with different
mechanisms of action, so the prognostic role of tumor-
associated immune cells could also differ. The included
studies had relatively small patients size, making it impos-
sible to stratify patients according to treatment modality or
tumor subsite. For some of the markers investigated in this
review, pathophysiological mechanisms have not been
clearly described yet, making interpretation of the prognos-
tic role difficult. A limitation for the meta-analysis con-
ducted for the classical markers was the reporting of
statistical information, as only four studies provided hazard
ratios. A trend in the selective reporting of p-values was
observed, which might indicate reporting bias and eventually
could lead to publication bias. Lastly, different NK cell sub-
sets are known, but the majority of studies in the classical
markers group only immunohistochemically stained CD56
or CD57. It would be beneficial to further characterize NK
cell subsets, to provide a better understanding of the tumor
microenvironment.
In conclusion, this systematic review and meta-analysis
found an overall favorable prognostic role of NK cells, char-
acterized by a different membrane and intracellular markers,
in HNSCC. Some studies implied the opposite, indicating the
fine balance between pro-and anti-tumor functions of NK
e1747345-6 S. K. BISHESHAR ET AL.
cells. Future studies should use homogeneous cohort regard-
ing tumor subsite and treatment modality, and use
a standardized method of reporting, in order to further pro-




The systematic search was conducted on the 7th of
March 2019 in two databases: Pubmed/Medline and
EMBASE. As domain, ‘head and neck squamous cell carci-
noma’ and synonyms of this term were used as determinant,
a variety of NK cell markers and their ligands were used
(Supplementary Table 1).
In- and exclusion criteria
Studies were screened based upon title and abstract. The final
selection was made by full-text reading of the selected articles.
Studies were eligible for inclusion if they assessed the prog-
nostic value of NK cell markers or their ligands in patients
with HNSCC (lip, OC, OP, HP, LP) by a time-to-event ana-
lysis, described as overall survival (OS), disease-free survival
(DFS), progression-free survival (PFS) or by correlation to
clinicopathologic characteristics. Nasopharyngeal carcinomas
were excluded due to the contributing role of epstein barr
virus (EBV) in the tumorigenesis. Only original articles pub-
lished in English were included. Animal studies, case reports,
reviews, meta-analyses or repetitive studies were excluded.
Conference abstracts and studies that used techniques other
than immunohistochemistry were excluded. The title/abstract
screening and full-text reading were conducted by two inde-
pendent researchers (ERU and SKB) and any disagreements
were resolved by discussion.
Data extraction
From the references selected by full-text screening the follow-
ing data were extracted: author’s last name, year of publica-
tion, biomarkers, sample size, tumor subsite, tumor stage,
HPV status, treatment modalities, median follow-up time,
methods, scoring methods for the immunohistochemically
stained samples, confounders, hazard ratios, confidence inter-
vals, and p-values. These data were entered in a standardized
form creating a synopsis of all relevant articles.
Outcome
NK cell markers and their ligands were organized in four
groups: ‘classical,’ ‘activating,’ ‘inhibiting,’ and ‘death recep-
tors.’ The classical group comprised CD56, CD57, CD16; the
activating group NKp46, CD70; the inhibiting group
CEACAM1, RCAS1; the death receptor group Fas, Fas-L,
FADD, TRAIL, TRAL-R, FAP1. Our study focused on the
classical markers as the primary outcome, strengthened by
a meta-analysis. The other makers were evaluated in
a narrative manner.
Critical appraisal
To assess the risk of bias of the prognostic studies included in
the meta-analysis, the Quality in Prognosis studies (QUIPS)
tool was used as described by Hayden et al. (2006).97 The
QUIPS tool comprises six items: study participation, attrition,
prognostic factor measurement, outcome measurement, con-
founding and statistical analysis and reporting. For each of
these items, the risk of bias was scored as low, moderate, or
high. Taking into consideration our research question, we
valued statistical analysis and reporting as most important
when assessing the overall risk of bias, because the meta-
analysis depended on the reporting of hazard ratios (HR).
Statistical analysis
In the meta-analysis, we used HR’s that were defined by high
NK cells vs low NK cells. If the study mentioned HR’s as low
NK cells vs high NK cells, we used the reciprocal. The meta-
analysis was performed in review manager 5.3 by use of
a random effect analysis.
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